Name: ATOSSA THERAPEUTICS INC (ATOS) Stock
Brand: ATOSSA THERAPEUTICS INC
Rating: 3.5 (3 reviews)

ATOS Latest News, Press Relases and Analysis

All

Press Releases

15 days ago - By: Atossa Therapeutics Inc

Atossa Highlights Emerging Opportunity for (Z)-Endoxifen in Duchenne Muscular Dystrophy, Including Symptomatic Female Carriers, Following Peer-Reviewed Publication and Scientific Presentation

20 days ago - By: Atossa Therapeutics Inc

Atossa Therapeutics Reports Third Quarter 2025 Financial Results and Provides a Corporate Update

a month ago - By: Atossa Therapeutics Inc

Atossa Therapeutics Highlights Progress in RECAST™ DCIS Platform Trial at Early Detection Research Conference; Laura Esserman, MD, MBA, to Discuss Active-Surveillance Strategy and Novel Endocrine Agents

2 months ago - By: Atossa Therapeutics Inc

Atossa Therapeutics to Present at the Maxim Growth Summit 2025

2 months ago - By: Atossa Therapeutics Inc

Atossa Advances Global Patent Strategy for Z-Endoxifen with New Protection in Israel and Ongoing Renewals

2 months ago - By: Atossa Therapeutics Inc

Atossa Therapeutics Streamlines EVANGELINE Breast Cancer Clinical Trial to Prioritize for 2026 NDA-Enabling Activities

2 months ago - By: Atossa Therapeutics Inc

Atossa Therapeutics Names Janet R. Rea, MSPH, as Senior Vice President, R&D to Accelerate (Z)-Endoxifen Toward Key Regulatory Milestones

3 months ago - By: Atossa Therapeutics, Inc.

Atossa Therapeutics Appoints CORE IR for Investor Relations, Shareholder Communications and Public Relations Services

3 months ago - By: Atossa Therapeutics Inc

Atossa Therapeutics Announces Regulatory Strategy Aimed at Accelerating Development of Low-Dose (Z)-Endoxifen for Breast Cancer Risk Reduction

3 months ago - By: ACCESS Newswire - Mentions: NB

NioCorp and Atossa Therapeutics Interviews to Air on the RedChip Small Stocks, Big Money(TM) Show on Bloomberg TV

3 months ago - By: Atossa Therapeutics Inc

Atossa Therapeutics CEO to Discuss Clinical Progress and Upcoming Milestones at 27th Annual H.C. Wainwright Global Investment Conference

3 months ago - By: Atossa Therapeutics Inc

Atossa Therapeutics Selects PSI as Contract Research Organization for Pivotal Dose-Ranging Study of (Z)-Endoxifen in Metastatic Breast Cancer

4 months ago - By: ACCESS Newswire - Mentions: CLDI

Atossa Therapeutics and Calidi Biotherapeutics Interviews to Air on the RedChip Small Stocks, Big Money(TM) Show on Bloomberg TV

4 months ago - By: Atossa Therapeutics Inc

Atossa Therapeutics Announces Positive FDA Feedback, Advances Toward IND for (Z)-Endoxifen Clinical Program in ER+/HER2- Metastatic Breast Cancer

5 months ago - By: Yahoo Finance

Ascendiant Lifts Atossa Therapeutics, Inc. (ATOS) Target Citing Strong Liquidity

6 months ago - By: Benzinga - Mentions: TLX EE PH PYPD

This Excelerate Energy Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Thursday

6 months ago - By: Atossa Therapeutics Inc

Atossa Therapeutics to Present at the Jefferies Global Healthcare Conference

7 months ago - By: ACCESS Newswire

Join Atossa Therapeutics' Exclusive Live Investor Webinar and Q&A Session on May 22

7 months ago - By: Yahoo Finance - Mentions: ABNB BKNG MAR BMY ...

ABNB, BKNG, and MAR: Which Travel Giant Deserves a Spot in Investor Portfolios?

7 months ago - By: Zacks Investment Research - Mentions: CLOV

Are Medical Stocks Lagging Atossa Genetics (ATOS) This Year?

7 months ago - By: Atossa Therapeutics Inc

Atossa Therapeutics Announces Full Results from I‑SPY 2 Endocrine‑Optimization Sub‑Study Evaluating Low‑Dose (Z)‑Endoxifen

7 months ago - By: ACCESS Newswire - Mentions: AIMD

Atossa Therapeutics and Ainos Interviews to Air on the RedChip Small Stocks, Big Money(TM) Show on Bloomberg TV

7 months ago - By: Atossa Therapeutics, Inc.

Atossa Therapeutics Announces Issuance of U.S. Patent No. 12,281,056, Including 58 Claims Covering Various Formulations for its (Z)-endoxifen Portfolio

7 months ago - By: Atossa Therapeutics, Inc.

Atossa Therapeutics Proposes Potentially Groundbreaking Study Aimed at Reducing Interval Breast Cancer in High-Risk Women at AACR 2025

7 months ago - By: Atossa Therapeutics, Inc.

Atossa Therapeutics Announces Issuance of U.S. Patent No. 12,275,684, Further Strengthening (Z)-endoxifen Portfolio

8 months ago - By: Nona Biosciences

Nona Biosciences and Atossa Therapeutics Partner to Discover Next-Generation Antibody Therapies for Breast Cancer

8 months ago - By: Zacks Investment Research

All You Need to Know About Atossa Genetics (ATOS) Rating Upgrade to Buy

8 months ago - By: Atossa Therapeutics, Inc.

Atossa Therapeutics Announces Full Year 2024 Financial Results and Provides Corporate Update

8 months ago - By: Benzinga - Mentions: YQ ACCS VIOT VERB ...

Earnings Scheduled For March 25, 2025

9 months ago - By: Atossa Therapeutics, Inc.

Atossa Therapeutics to Report Fourth Quarter and Full Year 2024 Financial Results

9 months ago - By: Atossa Therapeutics, Inc.

Atossa Therapeutics Announces Plans to Pursue Metastatic Breast Cancer Indication for (Z)-Endoxifen and Continued Engagement with FDA on Additional Indications

10 months ago - By: Atossa Therapeutics, Inc.

Atossa Therapeutics Congratulates Board Director Dr. Tessa Cigler and Weill Cornell Medicine on CDC Grant to Enhance Breast Cancer Care

10 months ago - By: Atossa Therapeutics, Inc.